ART Advanced Research Technologies Inc.: ART's SoftScan Optical Breast Imaging System Meets Primary Endpoint in Landmark Tissue Characterization Study
14th Nov 2006, 14:16 GMT
MONTREAL, QUEBEC (MARKET WIRE)
ART Advanced Research Technologies Inc.: ART's SoftScan Optical Breast Imaging System Meets Primary Endpoint in Landmark Tissue Characterization Study related news:
- ART's SoftScan Optical Breast Imaging System Meets Primary Endpoint in Landmark Tissue Characterization Study — ArriveNet : Health
- ART Advanced Research Technologies Announces 2006 Third Quarter Financial Results — ArriveNet : Health
- ART Advanced Research Technologies Inc.: ART Advanced Research Technologies Announces 2006 Third Quarter Financial Results — Market Wire - Earnings Reports
- Mayo Clinic study observes normal aging process lowers breast cancer risk — EurekAlert! - Breaking News
- Tegal Announces Settlement in Trade Secret Litigation — NSTI nanoPRwire
- Surgical Biopsy May Reveal Cancer In Women With Rare But Benign Breast Condition — ScienceDaily Headlines
- Study: Red Meat May Increase Risk for Breast Cancer — NPR Topics: Health & Science
- Favrille Drug Misses Secondary Target — Pharmaceuticals News from StratCenter.com
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend — Market Wire - Pharmaceuticals and Biotech
- Kronos Begins Sale of Key Components to Russian Partner for Manufacturing of Air Purification Devices — ArriveNet : Press Releases
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech